Download PDF
Nervenheilkunde 2022; 41(06): 405-410
DOI: 10.1055/a-1811-8195
Schwerpunkt

Antikoagulation bei linksatrialer Katheterablation

Anticoagulation for left atrial catheter ablation
Matthias D. Zink
1   Medizinische Klinik I – Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum RWTH Aachen
2   Abteilung für Physiologie, Cardiovascular Research Institute Maastricht (CARIM), Niederlande
,
Karl Georg Häusler
3   Klinik für Neurologie, Universitätsklinikum Würzburg
4   Kompetenznetz Vorhofflimmern e. V. (AFNET), Münster
,
Ulrich Schotten
2   Abteilung für Physiologie, Cardiovascular Research Institute Maastricht (CARIM), Niederlande
4   Kompetenznetz Vorhofflimmern e. V. (AFNET), Münster
,
Paulus Kirchhof
5   Klinik für Kardiologie, Universitäres Herz- und Gefäßzentrum Hamburg, Universitätsklinikum Hamburg-Eppendorf
7   German Center for Cardiovascular Diseases (DZHK), partner site Hamburg-Kiel-Lübeck
› Author Affiliations
› Further Information
    Permissions and Reprints

ZUSAMMENFASSUNG

Die linksatriale Katheterablation ist eine etablierte rhythmuserhaltenden Behandlung bei Patienten mit Vorhofflimmern und anderen supraventikulären Rhythmusstörungen. Es verdichten sich Hinweise, dass eine rhythmuserhaltende Therapie zusätzlich zur Verbesserung der Lebensqualität und Linderung von vorhofflimmerassozierten Symptomen kardiovaskuläre Ereignisse wie etwa ischämische Schlaganfälle verhindern und zum Erhalt der kognitiven Funktion beitragen kann. Allerdings finden sich bei etwa einem Viertel der Patienten nach linksatrialer Vorhofflimmerablation mittels Kernspintomografie klinisch stumme akute zerebrale Ischämien und etwa 0,2–0,3 % aller abladierten Patienten erleiden periinterventionell eine zerebrale Ischämie mit manifesten neurologischen Defiziten. Eine optimale Antikoagulation zur Prävention thrombembolischer Ereignisse im Zuge einer linksatrialen Katheterablationen ist daher ein zentraler Bestandteil in einem ganzheitlichen Therapiekonzept. Im Rahmen des vorliegenden Artikels soll die Datenlage und insbesondere die Ergebnisse der vom AFNET koordinierten AXAFA-AFNET-5-Studie vorgestellt werden.

ABSTRACT

Left atrial catheter ablation is an established treatment for rhythm maintenance in patients with atrial fibrillation and other supraventricular arrhythmias. There is growing evidence that rhythm-preserving therapy, in addition to improving quality of life and relieving atrial fibrillation-related symptoms, may prevent cardiovascular events such as ischemic stroke and help to preserve cognitive function. However, clinically silent acute cerebral ischemia is found in about a quarter of patients after left atrial fibrillation ablation by MRI and an estimated 0.2–0.3 % of all ablated patients experience cerebral ischemia with manifest neurological deficits peri-intervention. Optimal anticoagulation to prevent thromboembolic events during left atrial catheter ablation is therefore a central element in a holistic therapy concept. In this article, the current evidence and the results of the AFNET-coordinated AXAFA-AFNET 5 study will be discussed.

Schlüsselwörter

Vorhofflimmern - linksatriale Katheterablation - Heparin - MRT - orale Antikoagulation

Key words

Atrial fibrillation - left atrial catheter ablation - oral anticoagulation - heparin - MRI


Publication History

Article published online:
07 June 2022

© 2022. Thieme. All rights reserved.

© Georg Thieme Verlag KG Stuttgart · New York
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Hindricks G, Potpara T, Dagres N. et al 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020 DOI: 10.1093/eurheartj/ehaa612
    CrossrefPubMedGoogle Scholar
  • 2 Brugada J, Katritsis DG, Arbelo E. et al 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41: 655-720
    CrossrefPubMedGoogle Scholar
  • 3 Andresen D. Deutscher Herzbericht 2020. Deutsche Herzstiftung e. V 2021
    PubMedGoogle Scholar
  • 4 Hindricks G, Camm J, Merkely B. et al The EHRA White Book. EHRA 2017
    PubMedGoogle Scholar
  • 5 Calkins H, Hindricks G, Cappato R. et al 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018; 20: e1-e160
    CrossrefPubMedGoogle Scholar
  • 6 Kirchhof P, Camm AJ, Goette A. et al Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med 2020 DOI: 10.1056/NEJMoa2019422
    CrossrefPubMedGoogle Scholar
  • 7 Metzner A, Suling A, Brandes A. et al Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST – AFNET 4 trial. Europace 2021 DOI: 10.1093/europace/euab200
    CrossrefPubMedGoogle Scholar
  • 8 Noseworthy PA, Kapa S, Deshmukh AJ. et al Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: A propensity-matched study of 24,244 patients. Heart Rhythm 2015; 12: 1154-1161
    CrossrefPubMedGoogle Scholar
  • 9 Dagres N, Chao TF, Fenelon G. et al European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. J Arrhythm 2018; 34: 99-123
    CrossrefPubMedGoogle Scholar
  • 10 Bunch TJ, Crandall BG, Weiss JP. et al Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22: 839-845
    CrossrefPubMedGoogle Scholar
  • 11 Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke 2012; 43: 265-270
    CrossrefPubMedGoogle Scholar
  • 12 Cardoso R, Knijnik L, Bhonsale A. et al An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm 2018; 15: 107-115
    CrossrefPubMedGoogle Scholar
  • 13 Hohnloser SH, Camm J, Cappato R. et al Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J 2019; 40: 3013-3021
    CrossrefPubMedGoogle Scholar
  • 14 Cappato R, Marchlinski FE, Hohnloser SH. et al Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36: 1805-1811
    CrossrefPubMedGoogle Scholar
  • 15 Calkins H, Nordaby M. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med 2017; 377: 495-496
    PubMedGoogle Scholar
  • 16 Hausler KG, Eichner FA, Heuschmann PU. et al MRI-Detected Brain Lesions and Cognitive Function in Atrial Fibrillation Patients Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. Circulation 2022 DOI: 10.1161/CIRCULATIONAHA.121.056320
    CrossrefPubMedGoogle Scholar
  • 17 Herm J, Schurig J, Martinek MR. et al MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation – a retrospective analysis of prospective studies. BMC Cardiovasc Disord 2019; 19: 58
    CrossrefPubMedGoogle Scholar
  • 18 Häusler KG, Eichner FA, Heuschmann PU. et al MRI-Detected Brain Lesions and Cognitive Function in Atrial Fibrillation Patients Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. Circulation 2022 DOI: 10.1161/CIRCULATIONAHA.121.056320
    CrossrefPubMedGoogle Scholar
  • 19 Ren JF, Marchlinski FE, Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol 2004; 43: 1861-1867
    CrossrefPubMedGoogle Scholar
  • 20 Shah D. Filamentous thrombi during left-sided sheath-assisted catheter ablations. Europace 2010; 12: 1657-1658
    CrossrefPubMedGoogle Scholar
  • 21 Kuck KH, Fürnkranz A, Chun KR. et al Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J 2016; 37: 2858-2865
    CrossrefPubMedGoogle Scholar
  • 22 Kuck KH, Brugada J, Fürnkranz A. et al Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med 2016; 374: 2235-2245
    CrossrefPubMedGoogle Scholar
  • 23 Andrade JG, Champagne J, Dubuc M. et al Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation 2019; 140: 1779-1788
    CrossrefPubMedGoogle Scholar
  • 24 Tilz RR, Meyer-Saraei R, Eitel C. et al Novel Cryoballoon Ablation System for Single Shot Pulmonary Vein Isolation – The Prospective ICE-AGE-X Study. Circ J 2021; 85: 1296-1304
    CrossrefPubMedGoogle Scholar
  • 25 Shaban A, Leira EC. Neurological Complications of Cardiological Interventions. Curr Neurol Neurosci Rep 2019; 19: 6
    CrossrefPubMedGoogle Scholar
  • 26 Häusler KG. Schlaganfall als periprozedurale Komplikation kardialer Interventionen – Stroke during cardiac interventions. Nervenheilkunde 2020; 39: 836-842
    Article in Thieme ConnectGoogle Scholar
  • 27 Santangeli P, Di Biase L, Horton R. et al Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012; 05: 302-311
    CrossrefPubMedGoogle Scholar
  • 28 Kim JS, Jongnarangsin K, Latchamsetty R. et al The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol 2013; 06: 302-309
    CrossrefPubMedGoogle Scholar
  • 29 Yu HT, Shim J, Park J. et al When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. Eur Heart J 2019; 40: 1531-1537
    CrossrefPubMedGoogle Scholar
  • 30 Puwanant S, Varr BC, Shrestha K. et al Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009; 54: 2032-2039
    CrossrefPubMedGoogle Scholar
  • 31 Rathi VK, Reddy ST, Anreddy S. et al Contrast-enhanced CMR is equally effective as TEE in the evaluation of left atrial appendage thrombus in patients with atrial fibrillation undergoing pulmonary vein isolation procedure. Heart Rhythm 2013; 10: 1021-1027
    CrossrefPubMedGoogle Scholar
  • 32 Chen J, Zhang H, Zhu D. et al Cardiac MRI for detecting left atrial/left atrial appendage thrombus in patients with atrial fibrillation: Meta-analysis and systematic review. Herz 2019; 44: 390-397
    CrossrefPubMedGoogle Scholar
  • 33 Saksena S, Sra J, Jordaens L. et al A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography in patients with atrial fibrillation: the intracardiac echocardiography guided cardioversion helps interventional procedures study. Circ Arrhythm Electrophysiol 2010; 03: 571-577
    CrossrefPubMedGoogle Scholar
  • 34 Martinez MW, Kirsch J, Williamson EE. et al Utility of nongated multidetector computed tomography for detection of left atrial thrombus in patients undergoing catheter ablation of atrial fibrillation. JACC Cardiovasc Imaging 2009; 02: 69-76
    CrossrefPubMedGoogle Scholar
  • 35 Di Biase L, Burkhardt JD, Santangeli P. et al Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014; 129: 2638-2644
    CrossrefPubMedGoogle Scholar
  • 36 Antoniou CK, Manolakou P, Arsenos P. et al Antithrombotic Treatment after Atrial Fibrillation Ablation. Curr Pharm Des 2020; 26: 2703-2714
    CrossrefPubMedGoogle Scholar
  • 37 Verma A, Ha ACT, Kirchhof P. et al The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. Am Heart J 2018; 197: 124-132
    CrossrefPubMedGoogle Scholar